Register for free to
view the full innovation profile.
The vaccine creates a cytotoxic T-lymphocyte immune response against the tumor cells resulting in destruction of the HPV infected cells.
About
A Vaccine Therapeutic for Treatment of Cervical Cancer Description: Current State of the Art HPV 16 and 18 infections are primarily responsible for 70% cases of cervical cancer. Present treatment options majorly involve surgery and radiation therapy. Chemotherapeutic agents are sometimes used in combination with the former two treatment options. Problem with the Current Art Surgery on reproductive organs often complicate post-surgery consequences and may not prevent recurrence. Chemotherapeutic agents could possibly serve as an alternative to the existing treatment options. However lack of selectivity and severe side effects are major limitations for their use. Advantage of Invention This invention provides immunogenic synthetic peptide vaccine consisting of amino acids 13 through 21, and derivatives thereof, of the HPV 18 E6 protein. The vaccine creates a cytotoxic T-lymphocyte immune response against the tumor cells resulting in destruction of the HPV infected cells. GRU #2015-015